Multiple markers for melanoma progression regulated by DNA methylation: Insights from transcriptomic studies

Carcinogenesis

Volumn 26, Issue 11, 2005, Pages 1856-1867

  Gallagher, William M ^a   Rafferty, Mairin ^a   Kelly, Zoe D ^a   Nolan, Ilse Maria ^a   Fox, Edward J P ^a   Culhane, Aedin C ^a   McArdle, Linda ^b   Fraga, Mario F ^c   Hughes, Linda ^a   Currid, Caroline A ^a   O'Mahony, Fiona ^a   Byrne, Aileen ^a   Murphy, Alison A ^a   Moss, Catherine ^a   McDonnell, Susan ^a   Stallings, Raymond L ^b   Plumb, Jane A ^d   Esteller, Manel ^b   Brown, Robert ^d   Dervan, Peter A ^a   Easty, David J ^a   more..

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA; METHYLTRANSFERASE INHIBITOR;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; EARLY CANCER; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INCIDENCE; MARKER GENE; MELANOMA; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SKIN CARCINOGENESIS; STATISTICAL SIGNIFICANCE; TRANSCRIPTOMICS; UNINDEXED SEQUENCE; XENOGRAFT; Y CHROMOSOME;

ANIMALS; AZACITIDINE; CELL CYCLE PROTEINS; DISEASE PROGRESSION; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; RNA, NEOPLASM; SKIN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 27744548525     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi152     Document Type: Article

References (57)

1. Tucker,M.A. and Goldstein,A.M. (2003) Melanoma etiology: Where are we? Oncogene, 22, 3042-3052.
2. Beddingfield,F.C (2003) The melanoma epidemic: Res ipsa loquitur. Oncologist, 8, 459-465.
3. Chin,L., Merlino,G. and DePinho,R.A. (1998) Malignant melanoma: Modern black plague and genetic black box. Genes Dev., 12, 3467-3481.
4. Chung,C.H., Bernard,P.S. and Perou,C.M. (2002) Molecular portraits and the family tree of cancer. Nat. Genet., 32 (suppl.), 533-540.
5. Baldi,A., Santini,D., Uca Ade,L. and Paggi,M.G. (2003) cDNA array technology in melanoma: An overview. J. Cell Physiol., 196, 219-223.
6. Bittner,M., Meltzer,P., Chen,Y. et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature, 406, 536-540.
7. Clark,E.A., Golub,T.R., Lander,E.S. and Hynes,R.O. (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature, 406, 532-535.
8. Su,Y.A., Bittner,M.L., Chen,Y. et al. (2000) Identification of tumor-suppressor genes using human melanoma cell lines UACC903, UACC903(+6), and SRS3 by comparison of expression profiles. Mol. Carcinog., 28, 119-127.
9. Certa,U., Seiler,M., Padovan,E. and Spagnoli,G.C. (2001) High density oligonucleotide array analysis of interferon-alpha2a sensitivity and transcriptional response in melanoma cells. Br. J. Cancer, 85, 107-114.
10. Seftor,E.A., Meltzer,P.S., Kirschmann,D.A. et al. (2002) Molecular determinants of human uveal melanoma invasion and metastasis. Clin. Exp. Metastasis, 19, 233-246.
11. Wang,E., Miller,L.D., Ohnmacht,G.A. et al. (2002) Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res., 62, 3581-3586.
12. Baldi,A., Battista,T., De Luca,A. et al. (2003) Identification of genes down-regulated during melanoma progression: A cDNA array study. Exp. Dermatol., 12, 213-218.
13. van der Velden,P.A., Zuidervaart,W., Hurks,M. H. et al. (2003) Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int. J. Cancer, 106, 472-479.
14. Hsu,M.-Y., Elder,D.E. and Herlyn,M. (1999) Melanoma: The Wistar (WM) melanoma cell lines. In Masters,J.R.W. and Palsson,B. (eds) Human Cell Culture. Kluwer Academic Publishers, London, pp. 259-274.
15. Kobayashi,H., Man,S., MacDougall,J.R., Graham,C.H., Lu,C. and Kerbel,R.S. (1994) Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine-resistant phenotype. Am. J. Pathol., 144, 776-786.
16. Juhasz,I., Albelda,S.M., Elder,D.E. et al. (1993) Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am. J. Pathol., 143, 528-537.
17. Easty,D.J., Mitchell,P.J., Patel,K., Florenes,V.A., Spritz,R.A. and Bennett,D.C. (1997) Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma. Int. J. Cancer, 71, 1061-1065.
18. McArdle,L., Rafferty,M., Maelandsmo,G.M. et al. (2001) Protein tyrosine phosphatase genes downregulated in melanoma. J. Invest. Dermatol., 117, 1255-1260.
19. Breen,C.J., Barton,L., Carey,A. et al. (1999) Applications of comparative genomic hybridization in constitutional chromosome studies. J. Med. Genet., 36, 511-517.
20. Dasari,V.K., Deng,D., Perinchery,G., Yeh,C.C. and Dahiya,R.D. (2002) DNA methylation regulates the expression of Y chromosome specific genes in prostate cancer. J. Urol., 167, 335-338.
21. Fragra,M.F., Uriol,E., Borja Diego,L. et al. (2002) High-performance capillary electrophoretic method for the quantification of 5-methyl 2′-deoxycytidine in genomic DNA: Application to plant, animal and human cancer tissues. Electrophoresis, 23, 1677-1681.
22. Jin,H., Yang,R., Awad,T.A. et al. (2001) Effects of early angiotensin-converting enzyme inhibition on cardiac gene expression after acute myocardial infarction. Circulation, 103, 736-742.
23. Southern,E.M. (1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol., 98, 503-517.
24. Kath,R., Jambrosic,J.A., Holland,L., Rodeck,U. and Herlyn,M. (1991) Development of invasive and growth factor-independent cell variants from primary human melanomas. Cancer Res., 51, 2205-2211.
25. Balaban,G., Herlyn,M., Guerry,D.IV. et al. (1984) Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet. Cytogenet., 11, 429-439.
26. Balaban,G.B., Herlyn,M., Clark,W.H.Jr and Nowell,P.C. (1986) Karyotypic evolution in human malignant melanoma. Cancer Genet. Cytogenet., 19, 113-122.
27. Hildenbrand,R., Schroder,W., Brude,E., Schepler,A., Konig,R., Stutte,H.J. and Arnemann,H. (1999) Detection of TSPY protein in a unilateral microscopic gonadoblastoma of a Turner mosaic patient with a Y-derived marker chromosome. J. Pathol., 189, 623-636.
28. Lau,Y.F. (1999) Gonadoblastoma, testicular and prostate cancers, and the TSPY gene. Am. J. Hum. Genet., 64, 921-927.
29. Lau,Y. and Zhang,J. (2000) Expression analysis of thirty one Y chromosome genes in human prostate cancer. Mol. Carcinog., 27, 308-321.
30. Lau,Y.F., Lau,H.W. and Komuves,L.G. (2003) Expression pattern of a gonadoblastoma candidate gene suggests a role of the Y chromosome in prostate cancer. Cytogenet. Genome Res., 101, 250-260.
31. Liang,G., Gonzales,F.A., Jones,P.A., Orntoft,T.F. and Thykjaer,T. (2002) Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res., 61, 961-966.
32. Plumb,J.A., Strathdee,G., Sludden,J., Kaye,S.B. and Brown,R. (2000) Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 promoter. Cancer Res., 60, 6039-6044.
33. Krick,R., Jakubiczka,S. and Arnemann,J. (2003) Expression, alternative splicing and haplotype analysis of transcribed testis specific protein (TSPY) genes. Gene, 302, 11-19.
34. Arnemann,J., Jakubiczka,J., Thuring,S. and Schmidtke,J. (1991) Cloning and sequence analysis of a human Y-chromosome-derived, testicular cDNA, TSPY. Genomics, 11, 108-114.
35. Schneiders,F., Dork,T., Arnemann,J., Vogel,T., Werner,M. and Schmidtke,J. (1996) Testis-specific protein, Y-encoded (TSPY) expression in testicular tissues. Hum. Mol. Genet., 5, 1801-1807.
36. Zhang,J.S., Yang-Feng,T.L., Muller,U., Mohandas,T.K., de Jong,P.J. and Lau,Y.F. (1992) Molecular isolation and characterization of an expressed gene from the human Y chromosome. Hum. Mol. Genet., 1, 717-726.
37. Dasari,V.K., Goharderakhshan,R.Z., Perinchery,G. et al. (2001) Expression analysis of Y chromosome genes in human prostate cancer. J. Urol., 165, 1335-1341.
38. Baylin,S.B., Herman,J.G., Graff,J.R., Vertino,P.M. and Issa,J.P. (1998) Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv. Cancer Res., 72, 141-196.
39. Herman,J.G. and Baylin,S.B. (2003) Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 349, 2042-2054.
40. Momparler,R.L. (2003) Cancer epigenetics. Oncogene, 22, 6479-6483.
41. van der Velden,P.A., Metzelaar-Blok,J.A., Bergman,W. et al. (2001) Promoter hypermethylation: A common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res., 61, 5303-5306.
42. Zhou,X.P., Gimm,O., Hampel,H., Niemann,T., Walker,M.J. and Eng,C. (2000) Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol., 157, 1123-1128.
43. Soengas,M.S., Capodieci,P., Polsky,D. et al. (2001) Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature, 409, 207-211.
44. Karpf,A.R., Lasek,A.W., Ririe,T.O., Hanks,A.N., Grossman,D. and Jones,D.A. (2004) Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine. Mol. Pharmacol., 65, 18-27.
45. Zendman,A.J., van Kraats,A.A., den Hollander,A.I., Weidle,U.H., Ruiter,D.J. and van Muijen,G.N. (2002) Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis. Int. J. Cancer, 97, 195-204.
46. Serrano,A., Tanzarella,S., Lionello,I. et al. (2001) Re-expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int. J. Cancer, 94, 243-251.
47. Fulda,S., Kufer,M.U., Meyer,E., van Valen,F., Dockhorn-Dworniczak,B. and Debatin,K.M. (2001) Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene, 20, 5865-5877.
48. Suzuki,H., Gabrielson,E. and Chen,W. (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet., 31, 141-149.
49. Shi,H., Wei,S.H., Leu,Y. et al. (2003) Triple analysis of the cancer epigenome: An integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res., 63, 2164-2171.
50. Jones,P.A. and Baylin,S.B. (2002) The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3, 415-428.
51. Brown,R. and Strathdee,G. (2002) Epigenomics and epigenetic therapy of cancer. Trends Mol. Med., 8, S43-S48.
52. Smith,K.S., Folz,B.A., Adams,E.G. and Bhuyan,B.K. (1995) Synergistic and additive combinations of several antitumor drugs and other agents with potent alkylating agent adozelsin. Cancer Chemother. Pharmacol., 35, 471-482.
53. Kozar,K., Kaminski,R., Switaj,T. et al. (2003) Interleukin 12-based immunotherapy improves the antitumour effectiveness of a low-dose 5′-aza-2′-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin. Cancer Res., 9, 3124-3133.
54. Abele,R., Clavel,M., Dodion,P. et al. (1987) The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur. J. Cancer Clin. Oncol., 23, 1921-1924.
55. Anzai,H., Frost,P. and Abbruzzese,J.L. (1992) Synergistic cytotoxicity with 2′-deoxy-5-azacytidine and topotecan in vitro and in vivo. Cancer Res., 52, 2180-2185.
56. Coral,S., Sigalotti,L., Gasparollo,A., Cattarossi,I., Visintin,A. and Cattelan,A. (1999) Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR). J. Immunother., 22, 16-24.
57. Wang,E., Miller,L.D., Ohnmacht,G.A. et al. (2002) Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res., 62, 3581-3586.